Tratamiento óptimo. Lo que se pierde al no efectuarse.

Translated title of the contribution: First-line treatment. What is lost by not giving it

Francisco Lopez-Jimenez, M. A. Luna-Jiménez

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

It is highly desirable to give always the best therapeutic alternative. However, the accomplishment of this goal is not always possible, leaving the physician with second, third or no therapeutic choice at all. The reasons for this may be economic, logistic, medical and cultural. In order to know what the patients are losing, we need to test how strong the scientific evidence is for the first choice option, and second, we have to consider the magnitude of improvement on clinical outcomes, comparing the best therapy and the next best available therapy. In many instances, the difference in clinical benefit is small and even negligible.

Original languageSpanish
Pages (from-to)145-150
Number of pages6
JournalRevista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición
Volume49
Issue number2
StatePublished - Mar 1997
Externally publishedYes

Fingerprint

Medical Economics
Therapeutics
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Tratamiento óptimo. Lo que se pierde al no efectuarse. / Lopez-Jimenez, Francisco; Luna-Jiménez, M. A.

In: Revista de investigación clínica; organo del Hospital de Enfermedades de la Nutrición, Vol. 49, No. 2, 03.1997, p. 145-150.

Research output: Contribution to journalArticle

@article{ca923858ae034af593428d6aa2289e1f,
title = "Tratamiento {\'o}ptimo. Lo que se pierde al no efectuarse.",
abstract = "It is highly desirable to give always the best therapeutic alternative. However, the accomplishment of this goal is not always possible, leaving the physician with second, third or no therapeutic choice at all. The reasons for this may be economic, logistic, medical and cultural. In order to know what the patients are losing, we need to test how strong the scientific evidence is for the first choice option, and second, we have to consider the magnitude of improvement on clinical outcomes, comparing the best therapy and the next best available therapy. In many instances, the difference in clinical benefit is small and even negligible.",
author = "Francisco Lopez-Jimenez and Luna-Jim{\'e}nez, {M. A.}",
year = "1997",
month = "3",
language = "Spanish",
volume = "49",
pages = "145--150",
journal = "Revista de Investigacion Clinica",
issn = "0034-8376",
publisher = "Instituto Nacional de la Nutricion Salvador Zubiran",
number = "2",

}

TY - JOUR

T1 - Tratamiento óptimo. Lo que se pierde al no efectuarse.

AU - Lopez-Jimenez, Francisco

AU - Luna-Jiménez, M. A.

PY - 1997/3

Y1 - 1997/3

N2 - It is highly desirable to give always the best therapeutic alternative. However, the accomplishment of this goal is not always possible, leaving the physician with second, third or no therapeutic choice at all. The reasons for this may be economic, logistic, medical and cultural. In order to know what the patients are losing, we need to test how strong the scientific evidence is for the first choice option, and second, we have to consider the magnitude of improvement on clinical outcomes, comparing the best therapy and the next best available therapy. In many instances, the difference in clinical benefit is small and even negligible.

AB - It is highly desirable to give always the best therapeutic alternative. However, the accomplishment of this goal is not always possible, leaving the physician with second, third or no therapeutic choice at all. The reasons for this may be economic, logistic, medical and cultural. In order to know what the patients are losing, we need to test how strong the scientific evidence is for the first choice option, and second, we have to consider the magnitude of improvement on clinical outcomes, comparing the best therapy and the next best available therapy. In many instances, the difference in clinical benefit is small and even negligible.

UR - http://www.scopus.com/inward/record.url?scp=3242852217&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3242852217&partnerID=8YFLogxK

M3 - Article

C2 - 9380968

AN - SCOPUS:3242852217

VL - 49

SP - 145

EP - 150

JO - Revista de Investigacion Clinica

JF - Revista de Investigacion Clinica

SN - 0034-8376

IS - 2

ER -